Lisdexamfetamine's Efficacy in Treating Attention Deficit Hyperactivity Disorder (ADHD): A Meta-Analysis and Review
Heath Rutledge-Jukes1,2, Pallavi Jonnalagadda3, Andrew Paul McIntosh4
1Department of Psychiatry, Washington University School of Medicine, St. Louis, USA.
Cureus
|October 1, 2024
Summary
Lisdexamfetamine dimesylate effectively treats Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adults. This meta-analysis found no significant differences in efficacy across individual dosages or subscales of the ADHD Rating Scale-IV.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Attention-Deficit/Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder.
- Lisdexamfetamine dimesylate is a commonly prescribed stimulant for ADHD treatment.
- Previous analyses have not differentiated treatment effects on ADHD subscales or individual dosages.
Purpose of the Study:
- To conduct a meta-analysis on the efficacy of lisdexamfetamine dimesylate for ADHD.
- To analyze treatment effects on the inattentiveness and hyperactivity subscales of the ADHD Rating Scale-IV (ADHD-RS-IV).
- To evaluate the impact of individual lisdexamfetamine dimesylate dosages on ADHD symptom management.
Main Methods:
- A systematic meta-analysis of randomized-controlled trials published between 2007 and 2024.
- Inclusion criteria: English language, RCTs using ADHD-RS-IV for lisdexamfetamine efficacy in children and adults.
- Data sources: MEDLINE, Embase, Cochrane, PubMed, clinicaltrials.gov.
Main Results:
- Lisdexamfetamine dimesylate significantly alleviated ADHD symptoms compared to placebo, based on the full ADHD-RS-IV scale.
- No significant differences were observed in the efficacy of individual subscales (inattentiveness, hyperactivity).
- Analysis of individual dosages revealed no significant differences in ADHD symptom management across varying doses.
Conclusions:
- Lisdexamfetamine dimesylate is an effective treatment for ADHD symptoms in both pediatric and adult populations.
- Treatment efficacy is consistent across different dosages and does not significantly vary between the inattentiveness and hyperactivity subscales.
- The study provides a detailed meta-analysis of lisdexamfetamine dimesylate's efficacy, dose-response, and subscale effects in ADHD management.
Keywords:
adhdadhd-rs-ivadultschildrenhyperactivityinattentivenesslisdexamfetamine dimesylatemeta-analysissubscalesMore Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.7K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.3K
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
47
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
47
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
167
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
167
01:28Adrenergic Agonists: Mixed-Action Agents
678
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
678
01:25Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
106
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170